ImmunoVaccine Technologies, Inc. (IMV Inc.)
Works in GI & liver · Hematology · Immunology · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health
ImmunoVaccine Technologies, Inc. (IMV Inc.) is a clinical trial sponsor. It has 2 active clinical trials with 286 planned participants, across 8 therapeutic areas. Since 2021 it has completed 1 trial and stopped 2 early.
Trial track record · since 2021
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about ImmunoVaccine Technologies, Inc. (IMV Inc.)
ImmunoVaccine Technologies, Inc. (IMV Inc.) is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 286 planned participants, in GI & liver, Hematology, Immunology, Metabolic & endocrine and other areas. Since 2021 it has completed 1 trial and stopped 2 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with ImmunoVaccine Technologies, Inc. (IMV Inc.); every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2023-09-13.
Approve Suite is not affiliated with ImmunoVaccine Technologies, Inc. (IMV Inc.).
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.